REG - Medpal AI PLC - Eli Lilly Supply Agreement

Medpal AIAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260128:nRSb6289Qa&default-theme=true

RNS Number : 6289Q  Medpal AI PLC  28 January 2026

28 January 2026

MedPal AI plc

("MedPal AI" or the "Company")

Eli Lilly Supply Agreement

MedPal AI plc (AIM: MPAL), the AI-powered digital health company, is pleased
to announce that MedPal Limited, its wholly owned subsidiary, has been
approved as an authorised purchaser of Eli Lilly pharmaceutical products in
the United Kingdom.

The approval enables the Company to purchase and dispense Eli Lilly's
portfolio of medications, including Mounjaro® (tirzepatide), the GLP-1
receptor agonist approved for the treatment of type 2 diabetes and weight
management.

Market Opportunity

Mounjaro is the UK's leading weight loss medication, commanding approximately
79% of the UK GLP-1 market and research indicates that approximately ten times
more people in the UK purchase Mounjaro privately than receive it through the
NHS, highlighting the substantial commercial opportunity in the private
prescribing market. Alternative GLP-1 receptor Wegovy, which Medpal.clinic
already supplies, represents 20% of the market. This approval means that it
will now be able to offer GLP-1 patients their preferred medication.

The UK prescription weight loss medications market is forecast to grow from
approximately £340 million in 2025 to £2 billion by 2033, driven by rising
obesity prevalence and increasing adoption of GLP-1 therapies. An estimated
3.4 million people in the UK are eligible for tirzepatide treatment, with
approximately 64% of adults in England classified as overweight or obese.
Globally, the GLP-1 weight loss drugs market is projected to reach £120
billion by 2035. Direct supply access positions MedPal AI to serve the
significant and growing private market demand through MedPal.clinic, where
patients can access clinically supervised weight management pathways combining
AI-powered triage with prescriber consultation.

Operational Capability

Medications will be dispensed from the Company's distribution centre in
Swaffham, Norfolk, which utilises state-of-the-art robotic dispensing
technology to ensure accuracy, efficiency and rapid fulfilment of patient
orders. This automated infrastructure provides the scalability required to
meet anticipated demand growth.

This development supports the Company's strategy to position MedPal.clinic
(https://medpal.clinic/) as a leading digital platform for clinically
supervised weight management services, combining AI-powered patient triage
with access to innovative pharmaceutical treatments.

Jason Drummond, CEO of MedPal AI, commented:

"Securing direct supply rights with Eli Lilly, the manufacturer of the UK's
leading weight loss medication, is an important milestone for MedPal AI.
Access to Mounjaro strengthens our ability to serve patients through
MedPal.clinic, where our AI triage technology connects individuals with
appropriate clinical pathways for weight management. With our robotic
dispensing facility in Swaffham, we are well positioned to meet growing
patient demand."

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018). The Directors of the Company are
responsible for the contents of this announcement.

Enquiries:

 MedPal AI plc

 Jason Drummond, Chief Executive Officer     Via Square1 Consulting

 Cairn Financial Advisers LLP                +44 (0) 20 7213 0880

 Louise O'Driscoll/Jo Turner

 Clear Capital Markets Limited               +44 (0) 20 3869 6080

 Bob Roberts

 Square1 Consulting                          +44 (0) 20 7929 5599

 David Bick                                  +44 (0) 7831 381201

 

 

 

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven
wellness management. Its core app aggregates data from over 100 wearables and
health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile,
offering non-clinical, personalised lifestyle guidance through its AI wellness
coach. The Company is also developing conversational AI to provide
voice-based, real-time health insights, alerts, and recommendations.

Through its wholly owned subsidiary MedPal Limited, the Company operates a
24/7 AI-powered automated pharmacy distribution centre, providing nationwide
NHS and private prescription services. The facility leverages advanced robotic
dispensing technology integrated with AI triage to deliver rapid,
cost-effective medication fulfilment with same-day and next-day delivery
capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for
a limited time, grant exclusive, zero-cost access to the MedPal AI app across
Epassi's network of 11M+ employees at major firms like Siemens and Volvo.
Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare
providers, businesses, and insurers, with potential use in insurance-linked
wellness programs to reduce premiums and drive new revenue through
institutional partnerships. The Company also has a partnership agreement with
Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or
anticipated future events and anticipated results that are forward-looking in
nature and, as a result, are subject to certain risks and uncertainties, such
as general economic, market and business conditions, competition for qualified
staff, the regulatory process and actions, technical issues, new legislation,
uncertainties resulting from potential delays or changes in plans,
uncertainties resulting from working in a new political jurisdiction,
uncertainties regarding the results of exploration, uncertainties regarding
the timing and granting of prospecting rights, uncertainties regarding the
timing and granting of regulatory and other third party consents and
approvals, uncertainties regarding the Company's or any third party's ability
to execute and implement future plans, and the occurrence of unexpected
events.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGREAFFXAFEKEAA



            Copyright 2019 Regulatory News Service, all rights reserved